In patients with stage 2 CKD , adverse events were reported over 52 weeks by 83 patients ( 87 % ) on placebo ( 15 severe [ 16 % ] and 11 serious [ 12 % ] ) , 86 ( 88 % ) on empagliflozin 10 mg ( six severe [ 6 % ] and six serious [ 6 % ] ) and 78 ( 80 % ) on empagliflozin 25 mg ( eight severe [ 8 % ] and seven serious [ 7 % ] ) .